The small molecule inhibitor YK-4-279 was originally identified as a compound able to inhibit critical interactions between EWS-FLI1, the driver oncofusion in Ewing Sarcoma, and RNA Helicase A [30]. Here, DHX9 is linked to Ewing sarcoma.